Response to pneumococcal polysaccharide vaccine in patients with untreated Hodgkin's disease. Children's Cancer Study Group Report.
Patients with Hodgkin's disease (HD) have a high risk of overwhelming pneumococcal infections after splenectomy. Previous studies have shown that HD patients given polyvalent pneumococcal polysaccharide (PPS) vaccine after immunosuppressive therapy have a suboptimum antibody response. This study shows significant antibody response in HD patients to PPS vaccine given before radiation and chemotherapy. The same response was obtained whether the vaccine was given before or after splenectomy.
D000293:Adolescent; D000907:Antibodies, Bacterial / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D006689:Hodgkin Disease / Q000150:complications* / Q000276:immunology; D006801:Humans; D011008:Pneumococcal Infections / Q000517:prevention & control*; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D012306:Risk; D013156:Splenectomy / Q000009:adverse effects; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014611:Vaccination
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D011135:Polysaccharides, Bacterial